An official website of the United States government
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Edoxaban (Lixiana) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Apr.
| Yes/Good | Somewhat/Average | No/Poor | |
|---|---|---|---|
| Are the methods and analysis clear and transparent? | X | ||
| Comments Reviewer to provide comments if checking “no” | None | ||
| Was the material included (content) sufficient? | X | ||
| Comments Reviewer to provide comments if checking “poor” | None | ||
| Was the submission well organized and was information easy to locate? | X | ||
| Comments Reviewer to provide comments if checking “poor” | None | ||
| Authors of the Pharmacoeconomic Evaluation Submitted to CDR | |||
|---|---|---|---|
| □ Adaptation of global model/Canadian model done by the manufacturer ⊠ Adaptation of global model/Canadian model done by a private consultant contracted by the manufacturer □ Adaptation of global model/Canadian model done by an academic consultant contracted by the manufacturer □ Other (please specify) | |||
| Yes | No | Uncertain | |
| Authors signed a letter indicating agreement with entire document | X | ||
| Authors had independent control over the methods and right to publish analysis | X | ||
CDR = CADTH Common Drug Review.
Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
Your browsing activity is empty.
Activity recording is turned off.
See more...
